Call for Abstracts
:- |
|
| Guidelines for Abstract Submission |
|
| All abstracts submitted will go through a blind, peer-review process carried out by a review panel. The final selection of abstracts will be done by members of the Scientific Programme Committee in July 2010. All accepted abstracts will appear in their full form in the abstract book and on the conference websites. The CD-ROM will be available at the conference on payment basis. |
|
| Guidelines |
|
Please note the abstract submission guidelines should be read before submitting an abstract.
The deadline for abstract submission is 17.00 hrs IST of 15th July 2010. Abstracts will not be accepted after this date (except late breakers). Please submit your abstract online at www.icopa-india.org
The abstracts can be categorised on the basic theme of the work to presented. For categories of abstract please see the list of tracks (A -D) and categories.
Follow the guidelines listed on the website closely to avoid mistakes. To help you with your abstract submission, the following general guidelines have been drafted: |
- All abstracts must be written in English, typed using times new roman fonts with the size of 12.
- All abstracts must be submitted online through the conference website at www.icopa-india.org. Abstracts sent by fax, post or email will also be considered.
- For submission of abstracts online, you will have to register yourself first by clicking the Registration Form. After the successful registration login with your username & Password to submit your abstracts.
- It is the author’s responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as submitted by the author.
- Abstracts must not have been published or submitted for presentation to any other open national or international meeting. Accepted abstracts may not be published in any form or presented at any other open national or international meeting will not be considered.
- The text should not exceed 250 words.
|
| The text of the abstract should briefly state: |
- Objectives: indicate the purpose of the study or the hypothesis that was tested.
- Methods: include the setting for the study, the subjects, the diagnosis or intervention, and the type of statistical analysis. if references are needed, they should be provided in the text,
- Results: present as clearly as possible the outcome of the study and statistical significance, if appropriate,
- Conclusions: briefly discuss the data and emphasize the significance of the results.
|
All abstracts should disclose primary findings and avoid, whenever possible, promissory statements such as “experiments are in progress” or “results will be discussed”.
A confirmation of acceptance or rejection will be sent to the presenting author. Only the presenting author will receive mail concerning the abstract and is responsible for informing all co-authors of the status of the abstract. Authors whose abstracts have been accepted will receive instructions for presenting their abstract.
If any difficulty in submission of abstract please contact the conference secretary at secretariat@icopa-india.org. |
| |
| Abstract Categories |
| Abstracts can be submitted under following tracks. |
| |
| Track A: HIV Basic Science |
| Scope and Objectives |
| This track will comprise all aspects of fundamental HIV biology and the opportunistic pathogens in AIDS. Areas of focus will include HIV infection and replication, transmission, pathogenesis, immune responses to HIV, genetic susceptibility to HIV and various co-infections. |
| |
| Basic Retrovirology |
A1. HIV-1: Attachment, receptors and co-receptors, penetration and tropism
A2. HIV-2: Attachment, receptors and co-receptors, penetration and tropism
A3. HIV diversity |
| |
| Immunology |
A4. Innate immunity
A5. Virus-specific immunity
A6. Cytokines & chemokines
A7. Mucosal immunity/defenses |
| |
| Pathogenesis |
A8. Viral determinants of HIV pathogenesis
A9. Host genetics of resistance and susceptibility
A10. Mechanisms of T cell depletion and dysfunction
A11. HIV latency, persistence and reservoirs |
| |
| HIV Vaccines & Microbicides |
A12. Pre-clinical development of HIV vaccines
A13. Pre-clinical development of HIV microbicides |
| |
| Drug Development |
A14. HIV drug development
A15. Pre-clinical drugs and drug interactions
A16. Mechanisms of antiviral resistance |
| |
| Basics of HIV Transmission and Co-infections |
A17. HIV-1 and HIV-2 co-infection
A18. Parent-to-child transmission
A19. Inter-and intra-subtype co-infections
A20. HIV-hepatitis B virus interactions
A21. HIV-hepatitis C virus interactions
A22. HIV and Human herpes Viruses
A23. HIV and Mycobacterial co-infections
A24. HIV and Prozoan co-infections
A30. Other co-pathogens |
| |
| Track B: Clinical Research, Treatment and Care |
| Scope and Objectives |
| This track will highlight the latest research findings, related to the diagnosis, natural history and management of HIV as well as prevention, diagnosis and treatment of opportunistic infections/co-infections; antiretroviral therapy and immunotherapy including free ART provided by various governments and problems faced by patients. The track will also include new drug therapies, pharmacokinetics, drug interactions, adherence, adverse events, drug resistance, care and support in specific populations. Innovations related to diagnosis and provisions of HIV care in resource-limited settings will be addressed. |
| |
| Course of Infection and Disease |
B1. Prognostic staging of disease
B2. Disease burden-morbidity/mortality
B3. Parent-to-child transmission (Management issues) |
| |
| Diagnosis and Monitoring Tools |
B4. Voluntary counselling and testing including new CDC guidelines
B5. Diagnostic and laboratory monitoring tools specially in the context of resource-poor settings
B6. Immune Reconstitive Syndromes
B7. Viral resistance testing facilities and guidelines |
| |
| HIV- Associated Diseases |
B8. Opportunistic infections (excluding TB)
B9. Mycobacterial (including TB and MAC) infections
B10. Neurologic manifestations
B11. Malignancies (KS, lymphoma, cervical and anal carcinoma)
B12. Recent understanding of treating co-pathogen to reduce HIV transmission.
B13. Psychiatric and psychological conditions in AIDS |
| |
| Therapeutic and Disease Management Issues |
B14. Treatment interruptions, CD4 guided therapy
B15. Nutrition, complementary therapy
B16. Traditional medicines, yoga, Siddha etc
B17. Palliative care/Terminal care , Home care/Nursing and holistic care
B18. Issues related to Populations difficult to treat and difficult to counsel
B19. Pre- and Post- exposure prophylaxis
B20. Legal provisions including pre-marital mandatory testing |
| |
| Track C: Opportunistic Infections in Bone marrow and Stem cell recipients |
C1. Fungal and bacterial infections
C2. Viral and Parasitic infections |
| |
| Track D: Opportunistic Infections in Solid Organ (Kidney, Liver, Heart ) Transplant recipients |
D1. Fungal and bacterial infections
D2. Viral and Parasitic infections |
| |
| Track E: Opportunistic Infections in Miscellaneous immunosuppressive conditions |
| |
Immunology Foundation Award
The Organizing Committee is pleased to announce that with the help
from Immunology Foundation, two best abstracts and presentation will
be awarded. A scientific jury will select the oral presentation and
best poster from the respective sessions for the Award. Outstanding
research can be submitted as late breaker as email attachment. |
| |
